Active, not recruitingPhase 2NCT00070499
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Brian J DrukerSWOG Cancer Research Network
- Intervention
- Dasatinib(drug)
- Enrollment
- 406 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2004 – 2010
Study locations (20)
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Kaiser Permanente-Oakland, Oakland, California, United States
- Kaiser Permanente-Redwood City, Redwood City, California, United States
- Kaiser Permanente-Richmond, Richmond, California, United States
- Kaiser Permanente-Roseville, Roseville, California, United States
- Kaiser Permanente-South Sacramento, Sacramento, California, United States
- Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
- Kaiser Permanente-San Francisco, San Francisco, California, United States
- Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States
- Kaiser Permanente San Leandro, San Leandro, California, United States
- Kaiser Permanente-San Rafael, San Rafael, California, United States
- Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00070499 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics